Download PDF
Thromb Haemost 2022; 122(10): 1712-1722
DOI: 10.1055/a-1849-8477
Blood Cells, Inflammation and Infection

Hemorrhages in Polycythemia Vera and Essential Thrombocythemia: Epidemiology, Description, and Risk Factors—Learnings from a Large Cohort

Christophe Nicol
1   Service d'Onco-Hématologie, Centre Hospitalier des Pays de Morlaix, Morlaix, France
,
Nadine Ajzenberg   *
2   Laboratoire d'Hématologie, Hôpital Bichat, APHP, Paris, France
,
Karine Lacut
3   Département de Médecine Interne et de Pneumologie, CHRU de Brest, Brest, France
4   Inserm, UnivBrest, CHRU de Brest, UMR1304, GETBO, Brest, France
,
Francis Couturaud
3   Département de Médecine Interne et de Pneumologie, CHRU de Brest, Brest, France
4   Inserm, UnivBrest, CHRU de Brest, UMR1304, GETBO, Brest, France
,
Eric Lippert   *
5   Laboratoire d'Hématologie, CHRU de Brest, Brest, France
,
Brigitte Pan-Petesch
4   Inserm, UnivBrest, CHRU de Brest, UMR1304, GETBO, Brest, France
6   Service d'Hématologie Clinique, Institut de Cancéro-Hématologie, CHRU de Brest, Brest, France
,
Jean-Christophe Ianotto   *
4   Inserm, UnivBrest, CHRU de Brest, UMR1304, GETBO, Brest, France
6   Service d'Hématologie Clinique, Institut de Cancéro-Hématologie, CHRU de Brest, Brest, France
› Author Affiliations Funding None.
› Further Information
    Permissions and Reprints

Abstract

Background The management of myeloproliferative neoplasms (MPNs) is based on the reduction of thrombotic risk. The incidence, impact, and risk factors of bleedings have been less studied.

Methods All patients with polycythemia vera (n=339) or essential thrombocythemia (n=528) treated in our center are included in OBENE (Observatoire BrEstois des NEoplasies myéloprolifératives) cohort (NCT02897297). Major bleeding (MB) and clinically relevant nonmajor bleeding (CRNMB) occurring after diagnosis were included, except after leukemic transformation.

Results With a median follow-up of 8.3 years, incidence of hemorrhages was 1.85% patient/year, with an incidence of MB of 0.95% patient/year. The 10-year bleeding-free survival was 89%. The most frequent locations were digestive tract, “mouth, nose and throat,” and muscular hematoma. The case fatality rate of MB was 25%. The proportion of potentially avoidable postoperative bleeding was remarkable (17.6%). In multivariable analysis, eight risk factors of bleeding were identified: leukocytes >20 G/L at diagnosis (hazard ratio [HR]=5.13, 95% confidence interval [CI]: 1.77–14.86), secondary hemopathies (HR=2.99, 95% CI: 1.27–7.04), aspirin use at diagnosis (HR=2.11, 95% CI: 1.24–3.6), platelet count >1,000 G/L at diagnosis (HR=1.93, 95% CI: 1.11–3.36), history of hemorrhage (HR=1.82, 95% CI: 1.03–3.24), secondary cancers (HR=1.71, 95% CI: 1.01–2.89), atrial fibrillation (HR=1.66, 95% CI: 1.01–2.72), and male sex (HR=1.54, 95% CI: 1.02–2.33). The occurrence of a CRNMB increased the risk of a secondary MB (odds ratio=6.13, 95% CI: 2.86–12.6, p<0.00001). Most patients taking hydroxyurea displayed a nonmacrocytic median corpuscular value in the months preceding bleeding (51.4%).

Discussion The morbidity and mortality of bleedings in MPN should not be underestimated, and patients with platelet count >1,000 G/L and/or leukocytes >20 G/L, and possibly patients who suffered from a CRNMB could benefit from cytoreduction to reducing bleeding risk. Postoperative bleedings represent a substantial proportion of bleeding and could be better prevented.

Keywords

hemorrhage - polycythemia vera - essential thrombocythemia - risk factors

Author Contributions

C.N. and J.-C.I. elaborated the study, made statistics, and wrote the paper. B.P.-P., K.L., E.L., and N.A. critically reviewed the paper. F.C. helped in statistical analysis.


* France Intergroupe des Syndromes Myéloprolifératifs, Paris, France.


Supplementary Material



Publication History

Received: 17 September 2021

Accepted: 10 May 2022

Accepted Manuscript online:
11 May 2022

Article published online:
08 September 2022

© 2022. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Arber DA, Orazi A, Hasserjian R. et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 2016; 127 (20) 2391-2405
    Google Scholar
  • 2 Tefferi A, Guglielmelli P, Larson DR. et al. Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis. Blood 2014; 124 (16) 2507-2513
    CrossrefPubMedGoogle Scholar
  • 3 Tefferi A, Rumi E, Finazzi G. et al. Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study. Leukemia 2013; 27 (09) 1874-1881
    CrossrefPubMedGoogle Scholar
  • 4 Barbui T, Thiele J, Passamonti F. et al. Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study. J Clin Oncol 2011; 29 (23) 3179-3184
    CrossrefPubMedGoogle Scholar
  • 5 Mesa R, Jamieson C, Bhatia R. et al. Myeloproliferative Neoplasms, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2016; 14 (12) 1572-1611
    CrossrefPubMedGoogle Scholar
  • 6 Barbui T, Tefferi A, Vannucchi AM. et al. Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet. Leukemia 2018; 32 (05) 1057-1069
    CrossrefPubMedGoogle Scholar
  • 7 Martin K. Risk factors for and management of MPN-associated bleeding and thrombosis. Curr Hematol Malig Rep 2017; 12 (05) 389-396
    CrossrefPubMedGoogle Scholar
  • 8 Nicol C, Lacut K, Pan-Petesch B, Lippert E, Ianotto JC. Hemorrhage in essential thrombocythemia or polycythemia vera: epidemiology, location, risk factors, and lessons learned from the literature. Thromb Haemost 2021; 121 (05) 553-564
    Article in Thieme ConnectPubMedGoogle Scholar
  • 9 Appelmann I, Kreher S, Parmentier S. et al. Diagnosis, prevention, and management of bleeding episodes in Philadelphia-negative myeloproliferative neoplasms: recommendations by the Hemostasis Working Party of the German Society of Hematology and Medical Oncology (DGHO) and the Society of Thrombosis and Hemostasis Research (GTH). Ann Hematol 2016; 95 (05) 707-718
    CrossrefPubMedGoogle Scholar
  • 10 Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 2002; 100 (07) 2292-2302
    CrossrefPubMedGoogle Scholar
  • 11 Vardiman JW, Thiele J, Arber DA. et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009; 114 (05) 937-951
    CrossrefPubMedGoogle Scholar
  • 12 Berlin NI. Diagnosis and classification of the polycythemias. Semin Hematol 1975; 12 (04) 339-351
    PubMedGoogle Scholar
  • 13 Harris NL, Jaffe ES, Diebold J. et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol 1999; 17 (12) 3835-3849
    CrossrefPubMedGoogle Scholar
  • 14 Schulman S, Kearon C. Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 2005; 3 (04) 692-694
    CrossrefPubMedGoogle Scholar
  • 15 Kaatz S, Ahmad D, Spyropoulos AC, Schulman S. Subcommittee on Control of Anticoagulation. Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH. J Thromb Haemost 2015; 13 (11) 2119-2126
    CrossrefPubMedGoogle Scholar
  • 16 R: a language and environment for statistical computing. Accessed October 19, 2020 at: https://www.gbif.org/fr/tool/81287/r-a-language-and-environment-for-statistical-computing
    PubMedGoogle Scholar
  • 17 Bang SM, Lee JS, Ahn JY. et al; Korean MPN Working Party. Vascular events in Korean patients with myeloproliferative neoplasms and their relationship to JAK2 mutation. Thromb Haemost 2009; 101 (03) 547-551
    Article in Thieme ConnectPubMedGoogle Scholar
  • 18 De Stefano V, Za T, Rossi E. et al; GIMEMA CMD-Working Party. Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments. Haematologica 2008; 93 (03) 372-380
    CrossrefPubMedGoogle Scholar
  • 19 Chou YS, Gau JP, Yu YB. et al. Leukocytosis in polycythemia vera and splenomegaly in essential thrombocythemia are independent risk factors for hemorrhage. Eur J Haematol 2013; 90 (03) 228-236
    CrossrefPubMedGoogle Scholar
  • 20 Landolfi R, Marchioli R, Kutti J. et al; European Collaboration on Low-Dose Aspirin in Polycythemia Vera Investigators. Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med 2004; 350 (02) 114-124
    CrossrefPubMedGoogle Scholar
  • 21 Abdulla A, Davis WM, Ratnaweera N, Szefer E, Ballantyne Scott B, Lee AYY. A meta-analysis of case fatality rates of recurrent venous thromboembolism and major bleeding in patients with cancer. Thromb Haemost 2020; 120 (04) 702-713
    Article in Thieme ConnectPubMedGoogle Scholar
  • 22 Agnelli G, Buller HR, Cohen A. et al; AMPLIFY Investigators. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 2013; 369 (09) 799-808
    Google Scholar
  • 23 Patel MR, Mahaffey KW, Garg J. et al; ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365 (10) 883-891
    Google Scholar
  • 24 Fang MC, Go AS, Chang Y. et al. Death and disability from warfarin-associated intracranial and extracranial hemorrhages. Am J Med 2007; 120 (08) 700-705
    CrossrefPubMedGoogle Scholar
  • 25 Ruggeri M, Rodeghiero F, Tosetto A. et al; Gruppo Italiano Malattie Ematologiche dell'Adulto (GIMEMA) Chronic Myeloproliferative Diseases Working Party. Postsurgery outcomes in patients with polycythemia vera and essential thrombocythemia: a retrospective survey. Blood 2008; 111 (02) 666-671
    CrossrefPubMedGoogle Scholar
  • 26 Campbell PJ, MacLean C, Beer PA. et al. Correlation of blood counts with vascular complications in essential thrombocythemia: analysis of the prospective PT1 cohort. Blood 2012; 120 (07) 1409-1411
    CrossrefPubMedGoogle Scholar
  • 27 Franchini M, Mannucci PM. The never ending success story of tranexamic acid in acquired bleeding. Haematologica 2020; 105 (05) 1201-1205
    CrossrefPubMedGoogle Scholar
  • 28 Heyns M, Knight P, Steve AK, Yeung JK. A single preoperative dose of tranexamic acid reduces perioperative blood loss: a metaanalysis. Ann Surg 2021; 273 (01) 75-81
    CrossrefPubMedGoogle Scholar
  • 29 Kuint R, Levy L, Cohen GoichmanP. et al. Prophylactic use of tranexamic acid for prevention of bleeding during transbronchial lung biopsies – a randomized, double-blind, placebo-controlled trial. Respir Med 2020; 173: 106162
    CrossrefPubMedGoogle Scholar
  • 30 Devereaux PJ, Mrkobrada M, Sessler DI. et al; POISE-2 Investigators. Aspirin in patients undergoing noncardiac surgery. N Engl J Med 2014; 370 (16) 1494-1503
    CrossrefPubMedGoogle Scholar
  • 31 Chim CS, Kwong YL, Lie AKW. et al. Long-term outcome of 231 patients with essential thrombocythemia: prognostic factors for thrombosis, bleeding, myelofibrosis, and leukemia. Arch Intern Med 2005; 165 (22) 2651-2658
    CrossrefPubMedGoogle Scholar
  • 32 Lip GYH, Nieuwlaat R, Pisters R, Lane DA, Crijns HJGM. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on Atrial Fibrillation. Chest 2010; 137 (02) 263-272
    CrossrefPubMedGoogle Scholar
  • 33 De Stefano V, Ruggeri M, Cervantes F. et al. High rate of recurrent venous thromboembolism in patients with myeloproliferative neoplasms and effect of prophylaxis with vitamin K antagonists. Leukemia 2016; 30 (10) 2032-2038
    CrossrefPubMedGoogle Scholar
  • 34 Kaifie A, Kirschner M, Wolf D. et al; Study Alliance Leukemia (SAL). Bleeding, thrombosis, and anticoagulation in myeloproliferative neoplasms (MPN): analysis from the German SAL-MPN-registry. J Hematol Oncol 2016; 9: 18
    PubMedGoogle Scholar
  • 35 Hernández-Boluda JC, Arellano-Rodrigo E, Cervantes F. et al; Grupo Español de Enfermedades Mieloproliferativas Filadelfia Negativas (GEMFIN). Oral anticoagulation to prevent thrombosis recurrence in polycythemia vera and essential thrombocythemia. Ann Hematol 2015; 94 (06) 911-918
    CrossrefPubMedGoogle Scholar
  • 36 Tiede A, Rand JH, Budde U, Ganser A, Federici AB. How I treat the acquired von Willebrand syndrome. Blood 2011; 117 (25) 6777-6785
    CrossrefPubMedGoogle Scholar
  • 37 Mital A, Prejzner W, Bieniaszewska M, Hellmann A. Prevalence of acquired von Willebrand syndrome during essential thrombocythemia: a retrospective analysis of 170 consecutive patients. Pol Arch Med Wewn 2015; 125 (12) 914-920
    PubMedGoogle Scholar
  • 38 Mital A, Prejzner W, Świątkowska-Stodulska R, Hellmann A. Factors predisposing to acquired von Willebrand syndrome during the course of polycythemia vera - retrospective analysis of 142 consecutive cases. Thromb Res 2015; 136 (04) 754-757
    CrossrefPubMedGoogle Scholar
  • 39 Rottenstreich A, Kleinstern G, Krichevsky S, Varon D, Lavie D, Kalish Y. Factors related to the development of acquired von Willebrand syndrome in patients with essential thrombocythemia and polycythemia vera. Eur J Intern Med 2017; 41: 49-54
    CrossrefPubMedGoogle Scholar
  • 40 Layton AM, Sheehan-Dare RA, Goodfield MJ, Cotterill JA. Hydroxyurea in the management of therapy resistant psoriasis. Br J Dermatol 1989; 121 (05) 647-653
    CrossrefPubMedGoogle Scholar
  • 41 Joosten E. Iron deficiency anemia in older adults: a review. Geriatr Gerontol Int 2018; 18 (03) 373-379
    CrossrefPubMedGoogle Scholar
  • 42 Titmarsh GJ, Duncombe AS, McMullin MF. et al. How common are myeloproliferative neoplasms? A systematic review and meta-analysis. Am J Hematol 2014; 89 (06) 581-587
    CrossrefPubMedGoogle Scholar
  • 43 Tefferi A, Barbui T. Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management. Am J Hematol 2015; 90 (02) 162-173
    CrossrefPubMedGoogle Scholar
  • 44 Finazzi G, Carobbio A, Thiele J. et al. Incidence and risk factors for bleeding in 1104 patients with essential thrombocythemia or prefibrotic myelofibrosis diagnosed according to the 2008 WHO criteria. Leukemia 2012; 26 (04) 716-719
    CrossrefPubMedGoogle Scholar
  • 45 Kander EM, Raza S, Zhou Z. et al. Bleeding complications in BCR-ABL negative myeloproliferative neoplasms: prevalence, type, and risk factors in a single-center cohort. Int J Hematol 2015; 102 (05) 587-593
    CrossrefPubMedGoogle Scholar
  • 46 Borowczyk M, Wojtaszewska M, Lewandowski K. et al. The JAK2V617F mutational status and allele burden may be related with the risk of venous thromboembolic events in patients with Philadelphia-negative myeloproliferative neoplasms. Thromb Res 2015; 135 (02) 272-280
    CrossrefPubMedGoogle Scholar
  • 47 Kaifie A, Kirschner M, Wolf D. et al; Study Alliance Leukemia (SAL). Bleeding, thrombosis, and anticoagulation in myeloproliferative neoplasms (MPN): analysis from the German SAL-MPN-registry. J Hematol Oncol 2016; 9 (01) 18
    CrossrefPubMedGoogle Scholar
  • 48 Yesilova AM, Yavuzer S, Yavuzer H. et al. Analysis of thrombosis and bleeding complications in patients with polycythemia vera: a Turkish retrospective study. Int J Hematol 2017; 105 (01) 70-78
    CrossrefPubMedGoogle Scholar
  • 49 Marchioli R, Finazzi G, Landolfi R. et al. Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. J Clin Oncol 2005; 23 (10) 2224-2232
    CrossrefPubMedGoogle Scholar
  • 50 Alvarez-Larrán A, Pereira A, Guglielmelli P. et al. Antiplatelet therapy versus observation in low-risk essential thrombocythemia with a CALR mutation. Haematologica 2016; 101 (08) 926-931
    CrossrefPubMedGoogle Scholar
  • 51 Stein BL, Martin K. From Budd-Chiari syndrome to acquired von Willebrand syndrome: thrombosis and bleeding complications in the myeloproliferative neoplasms. Blood 2019; 134 (22) 1902-1911
    CrossrefPubMedGoogle Scholar
  • 52 Cerquozzi S, Barraco D, Lasho T. et al. Risk factors for arterial versus venous thrombosis in polycythemia vera: a single center experience in 587 patients. Blood Cancer J 2017; 7 (12) 662
    CrossrefPubMedGoogle Scholar
  • 53 Palandri F, Polverelli N, Catani L. et al. Bleeding in essential thrombocythaemia: a retrospective analysis on 565 patients. Br J Haematol 2012; 156 (02) 281-284
    CrossrefPubMedGoogle Scholar
  • 54 Wolanskyj AP, Schwager SM, McClure RF, Larson DR, Tefferi A. Essential thrombocythemia beyond the first decade: life expectancy, long-term complication rates, and prognostic factors. Mayo Clin Proc 2006; 81 (02) 159-166
    CrossrefPubMedGoogle Scholar
  • 55 Bertozzi I, Bogoni G, Biagetti G. et al. Thromboses and hemorrhages are common in MPN patients with high JAK2V617F allele burden. Ann Hematol 2017; 96 (08) 1297-1302
    CrossrefPubMedGoogle Scholar